The Prognosis For PepGen

Summary

• PepGen's stock has experienced extreme volatility, with an 80% drop, a 370% rebound, and subsequent decline in 14 months.
• The rebound was driven by news that Sarepta's DMD exon 51 candidate had lower skipping output than PepGen's PGN-EDO51.
• PepGen is focused on developing oligonucleotide therapies for severe neuromuscular and neurologic diseases, with two programs in human trials.
• A full investment analysis around PepGen follows in the paragraphs below.